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Hepatic resection for colorectal liver
metastases: prospective study
Objective. To assess the operative and long-term survival outcomes of hepatic
resection for colorectal liver metastases during an 11-year period in a tertiary
referral centre in Hong Kong.
Design. Prospective study.
Setting. University teaching hospital, Hong Kong.
Subjects and methods. Between January 1989 and December 1999, 72 patients
underwent hepatic resection for colorectal liver metastases. Clinical, pathological,
and outcome data were prospectively collected and analysed. Factors affecting
long-term survival were also evaluated.
Results. Twenty-five (34.7%) patients were found to have synchronous hepatic
metastasis at the time of colorectal resection. Fifty-two (72.2%) patients under-
went major hepatic resection. The operative morbidity and hospital mortality
rates were 19% and 4%, respectively. The 5-year survival rate after hepatectomy
was 31.9%. The median disease-free survival and median overall cumulative
survival were 18.5 months and 30.8 months, respectively. On multivariate analysis,
a high preoperative serum carcinoembryonic antigen level (>200 ng/mL) and
tumour involvement of the resection margin at histology were the two independ-
ent risk factors that adversely affected survival outcome.
Conclusion. Hepatic resection for colorectal liver metastases can be performed
safely, with minimal operative mortality and acceptable morbidity, and results in
satisfactory survival. High preoperative serum carcinoembryonic antigen level
and histological involvement of resection margin by cancer adversely affect the
survival outcome.
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Introduction
Colorectal cancer is the second most common cancer in Hong Kong, with an
incidence of 45.5 per 100 000 population in 1996.1 Liver metastasis frequently
occurs and is the major cause of treatment failure and death. Simultaneous
hepatic metastases have been observed in 11.5% of the patients undergoing
resection for primary colorectal cancer. Approximately 30% of the patients who
underwent apparently curative resection for the primary cancer subsequently
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developed liver metastases.2-4 Studies of the natural course
of the disease in patients with colorectal liver metastasis
have shown that untreated patients have a median survival
of 6 to 12 months, which would increase to 12 to 18 months
with chemotherapy.5-8 Hepatic resection is the most effect-
ive therapy for metastatic colorectal cancer, and is the
only curative therapy. Recent studies showed that liver
resection for metastatic colorectal cancer resulted in a
10-year survival of more than 20% and a 5-year survival for
one third of the patients.9,10
This study assessed the operative and long-term survival
outcomes of hepatic resection for colorectal liver metastases
during an 11-year period in a tertiary referral centre in Hong
Kong. Factors affecting long-term survival were also evaluated.
Subjects and methods
Between January 1989 and December 1999, 72 patients
with liver metastases from colorectal carcinoma underwent
hepatic resection in the Department of Surgery of Queen
Mary Hospital in Hong Kong.
Patients with synchronous hepatic metastasis were
considered for simultaneous hepatic resection if curative
resection was possible for all extrahepatic disease and a
limited hepatic resection was considered adequate. Patients
with metachronous liver metastasis and those who under-
went interval hepatic resection for synchronous metastasis
received preoperative evaluation for delineation of intra-
hepatic pathology and detection of extrahepatic disease.
Preoperative investigations included blood biochemistry,
carcinoembryonic antigen (CEA) assay, chest X-ray, per-
cutaneous ultrasonography, computed tomography (CT)
scan of the thorax and abdomen, and indocyanine green
(ICG) clearance test.
Hepatic resection followed the standard technique that
has been described previously11 and ultrasonic dissection
was used for parenchymal transection.12 For patients with
a large tumour situated at the right lobe of the liver, the
technique of anterior approach hepatic resection was
employed.13,14  All patients received the same perioperative
care by the same team of surgeons, and were nursed in the
intensive care unit during the early postoperative course. All
intra-operative complications and postoperative morbidities
were prospectively recorded. Hospital mortality was defined
as death during the same period of hospitalisation for
the hepatic resection. After hepatic resection, CEA assay,
ultrasonography, and chest X-ray were performed every 3
months for the first 2 years and then once a year. A CT
scan of the abdomen was also performed annually. Disease-
free survival time was calculated from the date of hepatic
resection to the date when recurrence was diagnosed.
For all patients, clinical data were prospectively re-
corded in a computerised database by a research assistant.
Statistical analysis included using the Chi squared test
or Fisher’s exact test to compare discrete variables and
the Mann-Whitney U test to compare continuous variables.
Multivariate analysis utilised the logistic regression model
and survival analysis was estimated by the Kaplan-Meier
survival method. Statistical analysis was performed with
the help of the Statistical Package for Social Science
(Windows version 10.0, SPSS Inc., Chicago, US). P values
of less than 0.05 were considered statistically significant.
Results
During the study period, 72 patients underwent hepatic
resection for colorectal liver metastasis. There were 51 men
and 21 women, with a median age of 61.5 years (range, 24-
78 years). The clinical data of the patients are summarised
in Table 1. Fifty-three (73.6%) patients had primary colonic
cancer and 19 (26.4%) had rectal cancer. The characteris-
tics of the primary carcinoma are summarised in Table 2.
Twenty-five patients were found to have synchronous
hepatic metastasis at the time of colorectal resection, six of
whom underwent synchronous minor hepatic resection
for small hepatic metastases. The other 19 patients plus
the remaining 47 patients who had metachronous liver
metastasis underwent interval hepatic resection, with a
median interval of 7.5 months.
Fifty-two (72.2%) patients underwent major hepatic
resections (ie resection of three or more liver segments by
Table 1. Clinical and biochemical characteristics of the study
population
Clinical/biochemical characteristic Data
No. of patients 72
Sex ratio (M:F) 51:21 (2.4:1)
Age* 61.5 (24-78)
Serum carcinoembryonic antigen* (ng/mL) 39.0 (1-3974)
Serum albumin* (g/L) 43.0 (33-55)
Serum total bilirubin* (µmol/L) 9.0 (3-39)
Aspartate aminotransferase* (U/L) 23.0 (10-180)
Haemoglobin* (g/dL) 13.4 (8.5-17.0)
Prothrombin time* (s) 11.0 (9.5-13.3)
Indocyanine green retention at 15 min* (%) 8.8 (1.1-21.2)
* Data expressed as the median (range)
Table 2. Characteristics of the primary carcinoma in the
study population
Characteristic Patients
No. (%)
Location
Caecum 5 (6.9)
Ascending colon 9 (12.5)
Hepatic flexure 3 (4.2)
Transverse colon 3 (4.2)
Splenic flexure 1 (1.4)
Descending colon 2 (2.8)
Sigmoid colon 29 (40.3)
Rectum 19 (26.4)
Hepatic flexure and splenic flexure 1 (1.4)
Dukes’ staging
A 3 (4.2)
B 18 (25.0)
C 24 (33.3)
Metastatic 25 (34.7)
Not defined 2 (2.8)
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Couinaud’s nomenclature15). Anterior approach hepatic
resection was performed for large right-lobe liver meta-
stasis in 12 (16.7%) patients and the intermittent Pringle
manoeuvre was employed in 28 (38.9%) patients. The patho-
logical data are outlined in Table 3. The median tumour-
free resection margin was 1 cm (range, 0-5 cm) and the
resection margin was involved at histology in 11 patients.
The operative morbidity and hospital mortality rates were
19% and 4%, respectively (Table 4). The three operative
deaths occurred early in the series (from 1989 to 1995), and
were related to liver failure and multi-organ failure (two
patients) and intra-abdominal sepsis secondary to bile
leakage (one patient).
All patients were followed up from the time of hepatic
resection to the time of preparation of the manuscript or
death. The 5-year survival rate was 31.9%. The median
disease-free survival and median overall cumulative survival
were 18.5 months and 30.8 months, respectively (Fig 1).
Twenty patients were still alive and disease-free with a
median follow-up of 42 months (range, 17-117 months).
The survival results of these 72 patients were not signifi-
cantly different from those of 473 patients who underwent
hepatic resection in Queen Mary Hospital for hepatocellu-
lar carcinoma during the same study period. The latter had
a median disease-free survival of 14.1 months (P=0.18 for
the comparison with the study population) and a median
overall cumulative survival of 43.2 months (P=0.58).
Statistical analysis was performed to identify the
factors affecting survival after hepatic resection in the
study population. Seventeen potential prognostic discrim-
inants were studied, including: patient factors (age, sex,
preoperative ICG clearance test, and serum total bilirubin);
tumour factors (preoperative serum CEA level, site of pri-
mary lesion, Dukes’ classification, location, size, number,
and time of hepatic metastases); and operative factors (time
and extent of hepatic resection, anterior approach hepatic
resection, intra-operative blood loss and transfusion
requirement, and width of tumour-free resection margin).
On multivariate analysis, a high preoperative serum CEA
level (>200 ng/mL) and an involvement of tumour in the
resection margin at histology were the two independent
risk factors that adversely affected the survival outcome
after hepatic resection for colorectal liver metastases.
Discussion
Hepatic resection has become an accepted form of surgical
therapy for patients with hepatic malignant tumours, with
low operative morbidity and mortality.16 Hepatic resection
for colorectal liver metastases has become a safe procedure,
with a reported mortality rate of less than 5% and accept-
able morbidity.9 The mortalities reported in this series
occurred early on in the study, and there has been no opera-
tive mortality after hepatic resection for colorectal liver
metastasis during the past 6 years. Selection criteria for pa-
tients with colorectal liver metastases to undergo hepatic
resection included the absence of extrahepatic metastasis,
satisfactory liver function, minimal co-morbid disease, and
technical feasibility for curative hepatic resection.
The 5-year survival rate of 31.9% for these patients is
far better than the expected survival for patients who do not
undergo hepatic resection,17,18 and is in accordance with the
5-year survival rate of approximately 30% reported in large
western series.9,19,20 The survival results were comparable
to those of patients with primary hepatocellular carcinoma
after hepatic resection in Queen Mary Hospital. With im-
proved understanding of the disease and its prognosis after
surgical resection, major centres in western countries experi-
enced an increased number of referrals of patients with
colorectal carcinoma for hepatic resection.10 The same in-
crease in referrals has not been experienced at Queen Mary
Table 3. Pathological data of the study population
Pathological data Value
Size of liver metastasis* (cm) 4.0 (1-16)
No. of liver metastasis* 1.0 (1 to >9)
Time of diagnosis
  Synchronous 25.0 (35%)
  Metachronous 47.0 (65%)
Interval between resection of primary tumour 7.5 (0-61)
  and detection of liver metastasis* (months)
Tumour-free resection margin* (cm) 1.0 (0-5)
Resection margin involved by tumour at histology 11.0 (15%)
* Data expressed as the median (range)
Table 4. Intra-operative and postoperative data of the study
population
Intra-operative/postoperative data Value
Intra-operative blood loss* (L) 1.3 (0.1-9.7)
Intra-operative blood transfusion* (L) 0.3 (0-8.6)
No. of patients without transfusion 31.0 (43.0%)
No. of patients with anterior approach 12.0 (17.0%)
  hepatectomy
Operating time* (min) 335.0 (120-750)
No. of patients with operative morbidity 14.0 (19.0%)
No. of patients with hospital mortality 3.0 (4.0%)
Median disease-free survival (months) 18.5
Median survival (months) 30.8
No. of patients with 5-year survival 23.0 (32.0%)
* Data expressed as the median (range)
Fig 1. Cumulative overall and disease-free survival in the
study population
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Hospital, however, despite there having been a significant
increase in the number of referrals of patients with hepato-
cellular carcinoma for hepatic resection (Fig 2). This lack
of uptake probably reflects a pessimistic attitude on the
part of clinicians and a poor understanding of the surgical
outcome of the disease. Certainly, surgical resection has been
regarded with great scepticism. Despite the satisfactory
survival outcome, it has been estimated that only about
one fifth of patients who might be potential candidates have
been referred for evaluation.21 Some of our patients, who
were not referred for any surgical opinion and were given a
guarded prognosis, came for medical advice after a long
post-diagnostic delay and subsequently underwent curative
hepatic resection. There were also patients who were re-
ferred to oncologists for ‘palliative care’ and were indirectly
referred to us for surgical resection.
Currently, there is no consensus as to the important
prognostic factors after hepatic resection for colorectal liver
metastases. Prognostic factors that have been identified
include patient factors, tumour factors, and operative factors.
With regard to tumour factors, for example, Hananel et al22
observed a better survival rate for patients with meta-
chronous metastases compared with those with synchronous
metastases. Fong et al10 identified seven factors that were
significant and independent predictors of poor long-term
outcome, including positive resection margin at histology;
extrahepatic disease; node-positive primary tumour; short
(<12 months) disease-free interval from primary tumour to
metastases; more than one liver metastasis; largest hepatic
tumour greater than 5 cm in size; and a CEA level above
200 ng/mL. In this study population, a high preoperative
serum CEA level (>200 ng/mL) and a resection margin
involved by tumour at histology were the two independent
risk factors that adversely affected survival after hepatic re-
section for colorectal liver metastases. Early referral and
surgical resection are therefore important for satisfactory
survival outcome. Surgical resection for liver metastases
should also be planned and performed carefully to obtain a
clear resection margin.
Local ablative therapies, including cryotherapy23,24 and
radiofrequency ablation,25,26 have been advocated for the
treatment of colorectal liver metastases. It is likely that
these techniques can produce complete destruction of small
lesions (<3 cm), although they may be less successful in
terms of curing larger tumours. Further studies are required
to document the role of ablative therapies in the care of pa-
tients with colorectal liver metastases. This notwithstanding,
since hepatic resection is the only documented treatment to
achieve a complete cure of the disease and is currently the
treatment of choice, it should be regarded as the standard
for the comparison of treatment of metastatic disease
isolated to the liver.
With the advent of new chemotherapeutic agents for
colorectal liver metastases, adjuvant chemotherapy after
hepatic resection may have a significant impact on improv-
ing patients’ survival, especially for patients who are pre-
dicted to have a poor outcome, for example, those with a
positive resection margin.7 Further studies are also required
on the role of regional adjuvant chemotherapy for this group
of patients.27,28
Conclusion
Hepatic resection for colorectal liver metastases can be
safely performed with minimal operative mortality and
acceptable morbidity, and results in satisfactory survival.
A high preoperative serum CEA level and tumour involve-
ment of resection margin at histology adversely affect the
survival outcome. Early referral and surgical treatment with
a clear resection margin are recommended.
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